Empaveli (pegcetacoplan) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults and children ages 12 and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). These are kidney diseases.

Fabhalta (iptacopan) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to reduce protein in the urine in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of their disease getting worse quickly and in adults with complement 3 glomerulopathy (C3G). Both are kidney diseases.

Filspari (sparsentan) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for certain kidney diseases, including primary immunoglobulin A nephropathy (IgAN) in adults and focal segmental glomerulosclerosis (FSGS) in adults and children aged 8 years and older.

Tarpeyo (budesonide) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for their disease getting worse.